Top-down approach to biological therapy of Crohn’s disease

References

• Rogler G. Top-down or step-up treatment in Crohn’s disease? Dig Dis. 2013;31(1):83–90.
   PubMed Web of Science ®Google Scholar
• Fascì Spurio F, Aratari A, Margagnoni G, et al. Early treatment in Crohn’s disease: do we have enough evidence to reverse the therapeutic pyramid? J Gastrointestin Liver Dis. 2012 Mar;21(1):67–73.
   PubMed Web of Science ®Google Scholar
• Markowitz J, Grancher K, Kohn N, et al. A multicenter trial of 6-mercaptopurine and prednisone in children with newly diagnosed Crohn’s disease. Gastroenterology. 2000;119:895–902.
   PubMed Web of Science ®Google Scholar
• Ramadas AV, Gunesh S, Thomas GA, et al. Natural history of Crohn’s disease in a population-based cohort from Cardiff (1986-2003): a study of changes in medical treatment and surgical resection rates. Gut. 2010;59:1200–1206.
   PubMed Web of Science ®Google Scholar
• Antunes O, Filippi J, Hébuterne X, et al. Treatment algorithms in Crohn’s - up, down or something else? Best Pract Res Clin Gastroenterol. 2014 Jun;28(3):473–483.
   PubMed Web of Science ®Google Scholar
• Cosnes J, Bourrier A, Laharie D, et al. Early administration of azathioprine vs conventional management of Crohn’s Disease: a randomized controlled trial. Gastroenterology. 2013 Oct;145(4):758–765.
   PubMed Web of Science ®Google Scholar
• Panés J, López-Sanromán A, Bermejo F, et al. Early azathioprine therapy is no more effective than placebo for newly diagnosed Crohn’s disease. Gastroenterology. 2013 Oct;145(4):766–774.
   PubMed Web of Science ®Google Scholar
• Gomollón F, Dignass A, Annese V, et al. EUROPEAN Evidence-based consensus on the diagnosis and management of Crohn’s disease 2016: part 1: diagnosis and medical management. J Crohns Colitis. cited 2016 Sep 22.
   Web of Science ®Google Scholar
• Jeuring S, Biemans V, Liu L, et al. Evolution of corticosteroid use in Crohn’s disease patients between 1991 and 2014: results from the dutch population-based inflammatory bowel disease south limburg cohort. ECCO. 2016;OP013.
   Google Scholar
• Chen QQ, Yan L, Wan J. Select a suitable treatment strategy for Crohn’s disease: step-up or top-down. Excli J. 2014 Feb;13(13):111–122.
   PubMed Web of Science ®Google Scholar
• D’Haens G, Baert F, van Assche G, et al. Early combined immunosuppression or conventional management in patients withnewly diagnosed Crohn’s disease: an open randomised trial. Lancet. 2008 Feb 23;371(9613):660–667.
   PubMed Web of Science ®Google Scholar
• Baert F, Moortgat L, van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010 Feb;138(2):463–468.
   PubMed Web of Science ®Google Scholar
• Rutgeerts P, van Assche G, Sandborn WJ, et al. Adalimumab induces and maintains mucosal healing in patients with Crohn’s disease: data from the EXTEND trial. Gastroenterology. 2012 May;142(5):1102–1111.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. Mucosal healing in inflammatory bowel disease. Rev Gastroenterol Dis. 2008;8:271–272.
   PubMedGoogle Scholar
• Landi B, Anh TN, Cortot A, et al. Endoscopic monitoring of Crohn’s disease treatment: a prospective, randomized clinical trial. Gastroenterology. 1992;102:1647–1653.
   PubMed Web of Science ®Google Scholar
• Papi C, Aratari A. Mucosal healing as a treatment for IBD? Expert Rev Gastroenterol Hepatol. 2014 Jul;8(5):457–459.
   PubMed Web of Science ®Google Scholar
• Solberg IC, Vatn MH, Hoie O, et al. Clinical course in Crohn’s disease: results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol. 2007;5:1430–1438.
   PubMed Web of Science ®Google Scholar
• Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012 Nov;61(11):1619–1635.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn’s disease. N Engl J Med. 2010 Apr 15;362(15):1383–1395.
   PubMed Web of Science ®Google Scholar
• Khanna R, Bressler B, Levesque BG, et al. Early combined immunosuppression for the management of Crohn’s disease (REACT): a cluster randomised controlled trial. Lancet. 2015 Nov 7;386(10006):1825–1834.
   PubMed Web of Science ®Google Scholar
• Matsumoto T, Motoya S, Watanabe K, et al. Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn’s disease: a prospective, multicentre, open-labelled clinical trial (DIAMOND study). Ecco. 2016;OP011.
   Google Scholar
• Allez M, Vermeire S, Mozziconacci N, et al. The efficacy and safety of a third anti-TNF monoclonal anti- body in Crohn’s disease after failure of two other anti-TNF antibodies. Aliment Pharma- Col Ther. 2010;31:92–101.
   PubMed Web of Science ®Google Scholar
• Ding NS, Hart A, de Cruz P. Systematic review: predicting and optimising response to anti-TNF therapy in Crohn’s disease - algorithm for practical management. Aliment Pharmacol Ther. 2016 Jan;43(1):30–51.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Marín AC, McNicholl AG, et al. Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther. 2015 Apr;41(7):613–623.
   PubMed Web of Science ®Google Scholar
• Moss AC. Optimizing the use of biological therapy in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf). 2015 Feb;3(1):63–68.
   PubMed Web of Science ®Google Scholar
• Vermeire S, Noman M, van Assche G, et al. Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn’s disease. Gut. 2007 Sep;56(9):1226–1231.
   PubMed Web of Science ®Google Scholar
• Steenholdt C, Bendtzen K, Brynskov J, et al. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016 Aug;22(8):1999–2015.
   PubMed Web of Science ®Google Scholar
• Schreiber S, Reinisch W, Colombel JF, et al. Subgroup analysis of the placebo-controlled CHARM trial: increased remission rates through 3 years for adalimumab-treated patients with early Crohn’s disease. J Crohns Colitis. 2013 Apr;7(3):213–221.
   PubMed Web of Science ®Google Scholar
• Hanauer SB, Feagan BG, Lichtenstein GR, et al. Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet. 2002;359:1541–1549.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn’s disease: the CHARM trial. Gastroenterology. 2007;132:52–65.
   PubMed Web of Science ®Google Scholar
• Panaccione R, Colombel JF, Sandborn WJ, et al. Adalimumab maintains remission of Crohn’s disease after up to 4 years of treatment: data from CHARM and ADHERE. Aliment Pharmacol Ther. 2013 Nov;38(10):1236–1247.
   PubMed Web of Science ®Google Scholar
• Juillerat P, Sokol H, Froehlich F, et al. Factors associated with durable response to infliximab in Crohn’s disease 5 years and beyond: a multicenter international cohort. Inflamm Bowel Dis. 2015 Jan;21(1):60–70.
   PubMed Web of Science ®Google Scholar
• Pariente B, Cosnes J, Danese S, et al. Development of the Crohn’s disease digestive damage score, the Lémann score. Inflamm Bowel Dis. 2011 Jun;17(6):1415–1422.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn’s disease recurrence after ileal resection. Gastroenterology. 2009 Feb;136(2):441–450.
   PubMed Web of Science ®Google Scholar
• Regueiro M, Kip KE, Baidoo L, et al. Postoperative therapy with infliximab prevents long-term Crohn’s disease recurrence. Clin Gastroenterol Hepatol. 2014 Sep;12(9):1494–1502.
   PubMed Web of Science ®Google Scholar
• Gasparetto M, Guariso G. Crohn’s disease and growth deficiency in children and adolescents. World J Gastroenterol. 2014 Oct 7;20(37):13219–13233.
   PubMed Web of Science ®Google Scholar
• Lee YS, Baek SH, Kim MJ, et al. Efficacy of early infliximab treatment for pediatric crohn’s disease: a three-year follow-up. Pediatr Gastroenterol Hepatol Nutr. 2012 Dec;15(4):243–249.
   PubMedGoogle Scholar
• Lee YM, Kang B, Lee Y, et al. Infliximab “Top-Down” strategy is superior to “Step-Up” in maintaining long-term remission in the treatment of pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2015 Jun;60(6):737–743.
   PubMed Web of Science ®Google Scholar
• Colombel JF, Siegel CA, Abhyankar B, et al. Safety of vedolizumab alone or with concomitant corticosteroids and/or immunosuppressants with ulcerative colitis or Crohn’s disease. United European Gastroenterol J. 2014;2:A82.
   Google Scholar
• Novacek G, Dejaco C, Gröchenig HP, et al. Vedolizumab in der behandlung der colitis ulcerosa und des morbus Crohn - ein konsensus der arbeitsgruppe “chronisch entzündliche darmerkrankungen” der österreichischen gesellschaft für gastroenterologie und hepatologie. Z Gastroenterol. 2016 May;54(5):456–467.
   PubMed Web of Science ®Google Scholar
• Rahier JF, Magro F, Abreu C, et al.; European Crohn’s and Colitis Organisation (ECCO). Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014 Jun;8(6):443–468.
   PubMed Web of Science ®Google Scholar
• Ford AC, Peyrin-Biroulet L. Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol. 2013;108:1268–1276.
   PubMed Web of Science ®Google Scholar
• Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn’s disease: TREAT registry. Clin Gastroenterol Hepatol. 2006 May;4(5):621–630.
   PubMed Web of Science ®Google Scholar
• Bonovas S, Fiorino G, Allocca M, et al. Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis. Clin Gastroenterol Hepatol. 2016 Oct;14(10):1385–1397.
   Web of Science ®Google Scholar
• Annese V, Beaugerie L, Egan L, et al.; ECCO. European evidence-based consensus: inflammatory bowel disease and malignancies. J Crohns Colitis. 2015 Nov;9(11):945–965.
   PubMed Web of Science ®Google Scholar
• Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929–936.
   PubMed Web of Science ®Google Scholar
• Cottone M, Kohn A, Daperno M, et al. Advanced age is an independent risk factor for severe infections and mortality in patients given anti-tumor necrosis factor therapy for inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011 Jan;9(1):30–35.
   PubMed Web of Science ®Google Scholar
• Beaugerie L, Carrat F, Colombel JF, et al.; CESAME Study Group. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut. 2014 Sep;63(9):1416–1423.
   PubMed Web of Science ®Google Scholar
• Kotlyar DS, Osterman MT, Diamond RH, et al. A systematic review of factors that contribute to hepatosplenic T-cell lymphoma in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol. 2011 Jan;9(1):36–41.
   PubMed Web of Science ®Google Scholar
• Osterman MT, Sandborn WJ, Colombel JF, et al. Increased risk of malignancy with adalimumab combination therapy, compared with monotherapy, for Crohn’s disease. Gastroenterology. 2014 Apr;146(4):941–949.
   PubMed Web of Science ®Google Scholar
• Silverstein MD, Loftus EV, Sandborn WJ, et al. Clinical course and costs of care for Crohn’s disease: markov model analysis of a population-based cohort. Gastroenterology. 1999;117:49–57.
   PubMed Web of Science ®Google Scholar
• Preiß JC, Bokemeyer B, Buhr HJ, et al. German Society of gastroenterology. updated German clinical practice guideline on “Diagnosis and treatment of Crohn’s disease” 2014. Z Gastroenterol. 2014 Dec;52(12):1431–1484.
   PubMed Web of Science ®Google Scholar
• Cullen G, O’toole A, Keegan D, et al. Long-term clinical results of ileocecal resection for Crohn’s disease. Inflamm Bowel Dis. 2007 Nov;13(11):1369–1373.
   PubMed Web of Science ®Google Scholar
• Aratari A, Papi C, Leandro G, et al. Early versus late surgery for ileo-caecal Crohn’s disease. Aliment Pharmacol Ther. 2007 Nov 15;26(10):1303–1312.
   PubMed Web of Science ®Google Scholar
• Pacilli M, Eaton S, Fell JM, et al. Surgery in children with Crohn disease refractory to medical therapy. J Pediatr Gastroenterol Nutr. 2011 Mar;52(3):286–290.
   PubMed Web of Science ®Google Scholar
• Newby EA, Sawczenko A, Thomas AG, et al. Interventions for growth failure in childhood Crohn’s disease. Cochrane Database Syst Rev. 2005 Jul 20;3:CD003873.
   Google Scholar
• Affronti A, Orlando A, Cottone M. An update on medical management on Crohn’s disease. Expert Opin Pharmacother. 2015 Jan;16(1):63–78.
   PubMed Web of Science ®Google Scholar
• Atreya R, Neumann H, Neufert C, et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn’s disease. Nat Med. 2014 Mar;20(3):313–318.
   PubMed Web of Science ®Google Scholar
• Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet. 2014 Jul 26;384(9940):309–318.
   PubMed Web of Science ®Google Scholar
• Simon EG, Ghosh S, Iacucci M, et al. Ustekinumab for the treatment of Crohn’s disease: can it find its niche? Therap Adv Gastroenterol. 2016 Jan;9(1):26–36.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ. New targets for small molecules in inflammatory bowel disease. Gastroenterol Hepatol (N Y). 2015 May;11(5):338–340.
   PubMedGoogle Scholar
• Kopylov U, Afif W, Cohen A, et al. Subcutaneous ustekinumab for the treatment of anti-TNF resistant Crohn’s disease–the McGill experience. J Crohns Colitis. 2014;8:1516–1522.
   PubMed Web of Science ®Google Scholar
• Tuskey A, Behm BW. Profile of ustekinumab and its potential in patients with moderate-to-severe Crohn’s disease. Clin Exp Gastroenterol. 2014;7:173–179.
   PubMedGoogle Scholar
• Heetun ZS, Keegan D, O’Donoghue D, et al. Report of successful use of ustekinumab in Crohn’s disease refractory to three anti-TNF therapies. Ir J Med Sci. 2014;183:507–508.
   PubMed Web of Science ®Google Scholar
• Harris KA, Horst S, Gadani A, et al. Patients with refractory Crohn’s disease successfully treated with Ustekinumab. Inflamm Bowel Dis. 2016;22:397–401.
   PubMed Web of Science ®Google Scholar
• Wils P, Bouhnik Y, Michetti P, et al. Subcutaneous Ustekinumab provides clinical benefit for twothirds of patients With Crohn’s disease refractory to anti-tumor necrosis factor agents. Clin Gastroenterol Hepatol. 2016;14:242–250 e2.
   PubMed Web of Science ®Google Scholar
• Monteleone G, Neurath MF, Ardizzone S, et al. Mongersen, an oral SMAD7 antisense oligonucleotide, and Crohn’s disease. N Engl J Med. 2015 Mar 19;372(12):1104–1113.
   PubMed Web of Science ®Google Scholar
• Efficacy and Safety Study of Mongersen (GED-0301) for the Treatment of Subjects With Active Crohn’s Disease. A Phase 3, Randomized, Placebo-controlled, Double-blind, Multicenter, Induction Study to Investigate the Efficacy and the Treatment of Subjects With Active Crohn’s Disease. https://clinicaltrials.gov/ct2/show/NCT02596893
   Google Scholar